Sample Submission Guidelines
Compare molecular responses across matched treatment conditions.
Start with the Decision Your Drug Study Needs to Make
The useful output is not simply a list of changed genes. It is a comparison that helps you decide whether compounds produce shared responses, diverge at particular doses, or trigger different programs as exposure continues. Those decisions determine which conditions need to enter the sequencing study.
For a compound series, the priority may be separating a common response from effects unique to one candidate. For a lead compound, it may be finding an informative sampling window before extensive cell loss. For a model-comparison study, it may be asking whether the same treatment-associated program appears across independently established cultures. Each requires a different set of comparisons, even when all use RNA sequencing.
| Your study decision | Useful comparison to plan | What the result contributes |
|---|---|---|
| Which compounds produce related molecular responses? | Each compound versus matched vehicle, followed by signature comparison | Groups candidates by observed expression response, not assumed target identity |
| When does a response become detectable? | Matched treated and vehicle samples at selected exposure times | Separates earlier and later expression changes within the sampled window |
| Does increasing exposure change the response program? | Selected doses with consistent timing and appropriate controls | Shows whether expression shifts strengthen, plateau, or change character |
| Is a response consistent across model sources? | Treatment contrasts within each source, with a planned cross-source comparison | Distinguishes shared findings from source-associated variation |
A short treatment matrix is often more useful than an indiscriminate expansion of conditions. We review the primary comparison first, then identify which additional controls or follow-up conditions are needed to interpret it. The broader organoid sequencing and analysis services page covers the surrounding molecular workflows; this service focuses on perturbation-to-response comparisons.
Choose DRUG-seq or Bulk RNA-seq Around the Required Readout
DRUG-seq is suited to studies in which many treatment conditions need comparable gene-level expression profiles. Conventional bulk RNA-seq remains an option when the question requires broader transcript coverage or a different RNA selection strategy. The choice should follow the biological question, not simply the number of wells available.
Gene-Level Profiling Across a Treatment Matrix
DRUG-seq uses sample indexing and pooled processing to make parallel expression profiling practical across multiple perturbations. Its published development established transcriptome-based comparisons as a way to organize compound responses beyond a single assay endpoint.[1] For organoids, the culture material, collection route, and selected implementation must still be assessed; a method demonstrated in conventional cell cultures does not establish every organoid sample's compatibility.
For a 3′ expression-counting implementation, concentrating reads near transcript ends supports gene-level comparisons across conditions. This is helpful when the question is whether stress, metabolism, cell-cycle, or other gene programs differ between treatments. It is not the preferred route for detailed splice-junction or transcript-isoform questions. Our DRUG-seq service provides the broader method context; this page adds the organoid exposure design and interpretation requirements.
Broader RNA Coverage for a Focused Follow-Up
Conventional mRNA sequencing can be considered when coverage across expressed transcript regions is important. If the study requires a different selection of RNA classes, total RNA sequencing may be more appropriate, subject to sample assessment and library design. Broader coverage does not by itself guarantee complete isoform resolution; the library and sequencing strategy must support the requested analysis.
Best for: comparing gene-expression responses across deliberately selected compounds, doses, times, or model sources. Not for: replacing a viability assay, proving direct compound–target binding, or assigning a bulk expression change to a specific cell population without additional evidence. Cell-resolved questions can be planned as a focused follow-up through single-cell RNA sequencing, rather than adding it to every condition by default.
Select Doses and Sampling Windows That Preserve Interpretability
An informative RNA profile depends on what remains in the culture at harvest. A late, strongly cytotoxic condition may describe surviving cells or a changed cell mixture rather than the initial response to the compound. Exposure selection therefore needs to consider model condition alongside the expression question.
Existing functional-screen results can help identify a useful range of exposures. A lower or intermediate condition may be informative for early pathway changes; a later condition may be needed to examine sustained responses or adaptation. Neither is universally superior. The design should state what each time point is intended to resolve and include the corresponding vehicle samples, because untreated cultures also change over time.
| Design choice | Why it affects interpretation | What to resolve before treatment |
|---|---|---|
| Concentration range | Large differences in cell loss can dominate apparent expression differences | Whether to compare equal concentrations, selected functional-effect levels, or both |
| Exposure duration | Early signaling-associated responses and later culture changes may differ | Which biological window each harvest represents |
| Solvent conditions | Vehicle effects can be confused with compound effects | Matched solvent concentration and any required additional controls |
| Model state at dosing | Passage, maturation, density, and culture condition influence response | A consistent starting state or a documented factor in the design |
| Harvest consistency | Collection delays can add variation unrelated to the planned exposure | The timing convention and order of sample collection |
Matching treatments by a similar functional effect can be useful, but it answers a different question from comparing the same concentration. We keep that choice explicit in the report. Apparent drug sensitivity also depends on baseline growth and assay duration; growth-rate metrics require suitable measurements and should not be inferred from an arbitrary endpoint viability signal.[2]
Build Controls and Replicates into the Treatment Map
Control placement and replicate definition should be settled before samples are pooled or treatment plates are assembled. Sequencing cannot recover a missing comparison, and more reads cannot separate a treatment effect from a batch effect when the two are completely confounded.
We map each sample to its model source, independent culture or preparation, treatment, dose, time point, and processing batch. Independently prepared biological replicates provide information about reproducibility; repeated measurements or wells derived from the same preparation have a different role. Pooling wells may help obtain sufficient material, but it does not automatically create independent replicates. The study record retains the pooling history.
Where practical, distribute treatment groups across processing batches and include the relevant controls within those batches. For several model sources, preserve the within-source treatment comparisons before assessing shared or source-dependent responses. A single pooled "control" assembled from unrelated sources can obscure the variation the study needs to measure.
Reference compounds may be included when they provide an interpretable biological comparison in the chosen model. They are not universal positive controls simply because they are familiar in another system. If combinations are included, single-agent conditions and an explicit combination question are needed; a combination-associated expression change alone does not establish pharmacological synergy.
From Compound Exposure to an Interpretable Response Profile
The workflow connects experimental decisions with a predefined analysis plan. Its checkpoints are intended to reveal problems while they can still affect sample selection, rather than discovering at the reporting stage that treatments cannot be compared fairly.
Select the library route around the required comparison.
- Define the exposure matrix. Confirm the model, compounds, selected doses, sampling windows, controls, and biological comparisons. Identify which functional observations or metadata will accompany the RNA results.
- Coordinate treatment and harvest. For agreed experimental work, align culture handling and sample collection with the planned contrasts. For externally treated material, review the available exposure records and collection method before submission.
- Assess the RNA or lysate route. Review material suitability for the selected method. Quality findings guide whether a sample can enter the planned comparison or requires a revised route.
- Prepare libraries and sequence. Use the agreed expression-counting or conventional RNA-seq strategy. Preserve sample identity through indexing and processing so results can be mapped back to their exposure conditions.
- Compare responses and report limitations. Review sample relationships, run the agreed differential analyses, interpret gene programs, and connect results to the treatment metadata and any matched functional observations.
Projects can begin with established organoids, an agreed treatment experiment, or already collected material. Model availability, experimental handling, and sample acceptance are scoped before the study starts. This makes it possible to coordinate the required components without implying that every culture format or compound can follow an identical protocol.
Prepare the Material and Exposure Record Together
The sample and its treatment history are one analytical unit. An RNA tube without a reliable dose, collection time, or control relationship may produce sequence data but still fail to answer the intended drug-response question.
| Provide for assessment | Why it is needed |
|---|---|
| Model identity, source, passage and relevant culture history | Places observed responses in the correct biological context |
| Compound identity, concentration with units, solvent and exposure duration | Defines the treatment contrast and allows comparisons to be reproduced |
| Vehicle, untreated or reference conditions and their purpose | Clarifies the baseline used for each analysis |
| Replicate IDs, plate map, pooling history and processing batches | Supports the statistical design and identifies possible confounding |
| Collection method, storage conditions and available material | Allows assessment against the selected RNA or lysate workflow |
| Matched morphology, viability or other functional observations, when available | Helps evaluate whether cell loss or culture changes accompany expression shifts |
For purified compounds, note formulation and any observed solubility or precipitation issues. For natural products or extracts, include batch identity, composition information when available, and vehicle conditions. An extract-associated signature characterizes the tested preparation; it does not identify which constituent produced the response.
Do not assume a medium, matrix, fixation method, or lysis reagent used successfully for another assay is compatible with the chosen sequencing route. Confirm the collection instructions before sacrificing material. Input requirements, sample numbers, sequencing allocation, and the feasibility of using stored material are determined for the selected workflow rather than fixed across all organoid studies.
Identify Expression Signatures and Response Programs
Analysis starts by checking whether samples behave consistently with the study design. Only then do gene lists and pathway summaries become useful for comparing treatments. A visually striking heatmap is not a substitute for sample-level review and an interpretable contrast.
Review Samples Before Ranking Genes
Quality summaries and sample-relationship plots help identify failed material, unexpected separation, or variation associated with processing rather than treatment. Decisions to retain or exclude samples are documented. If a low-quality group coincides with a particular exposure, removing it without explanation could hide a treatment-associated collection problem or bias the comparison.
Differential expression is evaluated using the agreed design and suitable count-based methods, with effect estimates and multiple-testing information reported alongside gene identifiers.[3] The model should reflect the available replicates and relevant design factors. If dose, time, model source, and batch are all of interest, the sample structure must support their separation; an underspecified experiment cannot be repaired by a more elaborate model.
Compare Patterns, Not Only Individual Hits
Response signatures organize gene-level changes by their direction and magnitude. Comparisons across compounds can reveal shared patterns, while dose- and time-specific contrasts show where a response changes. Pathway or gene-set analysis places those results in a biological framework, with the gene-set source, analysis approach, and supporting genes retained for review.
When reference compounds are included in the experiment, their response profiles can provide context for the other treatments. Similarity is a hypothesis-generating observation, not proof of the same direct target. Differences in exposure and sample condition can influence the match. Any comparison with an external reference dataset also requires an assessment of cell-system, assay-design, and gene-coverage differences.
Bulk profiles average the recovered sample. A stress-associated signature might reflect altered expression within cells, a changing proportion of cell states, or both. The report distinguishes these interpretations instead of assigning a cellular source that the assay did not measure.
Connect RNA Changes with Matched Functional Readouts
Expression profiling is most informative when it complements the phenotype that motivated the study. RNA results can explain what molecular programs accompany a response; a matched functional assay shows the measured effect under its own conditions. The two readouts should remain distinct even when they are presented together.
Connect separate assay wells through shared model and exposure metadata.
For destructive assays, plan separate RNA-designated and function-designated wells from matched cultures and exposures. Do not assume that a well consumed by an endpoint assay remains suitable for RNA profiling. Shared model, dose, time, and batch identifiers allow the datasets to be linked without pretending they came from the identical harvested material.
The organoid drug screening services page covers the functional screening component. Here, those observations provide context for the transcriptomic comparison. Organoid research has demonstrated the value of measuring drug-induced phenotypes beyond a single summary endpoint; adding molecular data is useful when it addresses a defined gap rather than simply increasing the number of assays.[4]
Concordant results can prioritize a focused validation experiment. Discordant results can also be informative: a pathway-associated response may occur without a large change in the chosen functional endpoint, or cell loss may dominate one condition's RNA profile. Neither situation should be forced into a positive mechanism claim. The next experiment follows the unresolved question, which may require a protein-level assay, genetic perturbation, or another functional measurement rather than additional bulk sequencing.
Receive a Comparison Package You Can Reuse
Deliverables are agreed at project setup so the final package supports both scientific review and subsequent analysis. The core is a traceable connection from sample identifiers to expression measurements, analysis contrasts, and the limitations attached to each comparison.
| Package component | How your team uses it |
|---|---|
| Agreed sequence-data files and sample-level QC summaries | Reviews data quality and retains the underlying material for reanalysis |
| Gene-level count matrix, annotations and analysis-ready metadata | Reproduces the treatment map and supports additional compatible comparisons |
| Differential expression tables with effect estimates and statistical information | Examines the evidence behind candidate genes rather than relying on a filtered list alone |
| Pathway or gene-set summaries with supporting genes | Evaluates which response programs explain the observed pattern |
| Compound, dose or time comparison plots included in scope | Communicates where responses converge or diverge across the experiment |
| Analysis methods, contrast definitions and interpretation notes | Separates measured findings, analytical choices and follow-up hypotheses |
For a discovery team, the report can organize candidates by response pattern and highlight conditions worth revisiting. For an analysis team, matrices and metadata preserve flexibility beyond the initial figures. For project coordination, a defined sample inventory and deliverable list make it clear which treatments were tested and which questions remain outside the study.
Illustrative Drug-Response Results
These examples show how results may be organized. They are conceptual illustrations, not customer data, acceptance criteria, or promised outcomes. The figures included in an actual project depend on its sample design and the analyses agreed in scope.
Illustrative example: compare dose- and time-associated response patterns.
Dose and Time Response Map
A compact heatmap compares selected expression programs across doses and sampling windows. It helps identify where a response becomes stronger or changes character. The underlying genes, contrast definitions, and statistical results remain necessary for interpretation; a color change alone does not establish a meaningful biological effect.
Illustrative example: organize compounds by measured response patterns.
Compound Signature Comparison
A similarity matrix groups treatments by the expression responses they produced in the tested model. It can guide which compounds merit a closer comparison. Related signatures do not establish shared target binding, and dissimilar signatures may reflect differences in exposure or sample condition as well as biology.
Illustrative example: retain functional and RNA measurements as complementary readouts.
Paired Functional and RNA Summary
Matched functional and expression summaries can show why two treatments with similar endpoint values still warrant different follow-up experiments. Each measurement retains its own units and controls. The comparison adds context; it does not convert a transcriptional response into an efficacy or safety conclusion.
Organoid Drug Transcriptomics FAQs
Can We Profile Only the Compounds That Passed Our Initial Screen?
Yes, a focused follow-up can be planned around a selected compound set. Include the matching controls and define why those conditions were chosen. If the goal is to understand what separates hits from non-hits, a relevant comparator outside the selected hit group may be necessary; profiling hits alone cannot answer that comparison.
Do We Need Both a Dose Series and a Time Course?
Not necessarily. Prioritize the variable needed for the main decision, then add conditions only when they resolve a specific uncertainty. One dose at one time can support a defined treatment contrast, but it cannot describe an entire dose-response relationship or establish how the response develops over time.
What If a Compound Changes Gene Expression but Not Viability?
That can be a useful finding, provided exposure and sample quality are adequate. Expression changes may precede the measured endpoint or involve biology that the selected assay does not capture. Review the supporting genes and controls, then choose a relevant follow-up measurement rather than treating any signature as proof of functional benefit.
Can RNA Profiling Demonstrate Drug Synergy?
Not on its own. Combination-associated expression changes can be compared with the single-agent conditions, but pharmacological synergy requires an appropriate functional design and analysis. A larger transcriptional change in a combination does not automatically mean the drugs act synergistically.
Can We Submit RNA Collected from a Previous Experiment?
Potentially, after review of RNA quality, storage history, and treatment metadata. Existing samples may support a useful comparison if the required controls and replicates were retained. Missing collection-time information or an unresolvable batch–treatment confound can limit interpretation even when the RNA passes laboratory quality checks.
Can We Compare Tumor and Non-Tumor Organoids?
Such a comparison can be scoped when the models, culture conditions, and treatment design support it. Compare each model with its appropriate baseline and retain source variation in the analysis. Differences between the models do not, by themselves, establish selective action or general safety beyond the tested experimental conditions.
Does a Similarity Match Reveal the Compound's Target?
No. A match can suggest related downstream responses and help organize a validation plan. Different perturbations may converge on the same stress or cell-cycle program. Establishing a direct target requires additional evidence appropriate to the proposed interaction, not expression similarity alone.
When Should We Add Single-Cell Profiling?
Consider it when identifying the responding cell population is essential, especially if treatment may change cell composition. A focused subset of conditions is often a more interpretable starting point than profiling every exposure. Harvest suitability and recovery bias still need assessment, particularly after treatments that reduce viability.
Case Study: Similar Lipid Reduction, Different Expression Programs
Source. Hendriks and colleagues, Nature Biotechnology (2023).[5] This is an independent published study, not a CD Genomics customer project.
Background. Similar changes in lipid accumulation did not establish whether different treatments produced the same molecular response.
Methods. The researchers profiled drug-treated, engineered hepatocyte organoids, including APOB-deficient lines from two donors, against vehicle controls.
Results. Treatments separated into distinct expression patterns, with transcriptome clustering and gene-set analysis distinguishing responses despite a shared lipid-reduction endpoint.
Conclusion. The study illustrates why a matched phenotype can benefit from an RNA-level comparison. Its findings support model-specific follow-up hypotheses, not a general guarantee of compound action in other systems.
Independent study figure: treatment-associated expression profiles and gene programs.
Figure 4 reproduced from Hendriks D, Brouwers JF, Hamer K, et al.[5] under the Creative Commons Attribution 4.0 International license. Scientific content unchanged; file format converted for web delivery. Original figure: publisher figure page.